Already inside the gate: the company is specified into someone else's next wave, and the wave has not yet shipped
The model's full reasoning — Q2 2017 call → NOWe need to determine if the transcript describes a situation where Biogen is already chosen/designed into another organization's future product/program, and that wave hasn't arrived yet, and it's large relative to Biogen. Let's scan the transcript for such descriptions. Key points: Biogen has licensing deals, acquisitions, partnerships. For example, BIIB092 from BMS, BIIB093 from Remedy, collaboration with Ionis, Eisai, Penn, etc. But the question is about being "inside another organization's future product, program, platform, build-out, or standard operating plan" such that when that outside party's next wave arrives, Biogen's volume arrives automatically. Look for specific mentions: For instance, Biogen's collaboration with Ionis for BIIB067 (antisense for ALS). But is that a case where Biogen is designed into Ionis's product? Actually, Biogen is the licensee, so it's Biogen's product. Not that. What about the biosimilar JV with Samsung Bioepis? Biogen has an option to increase investment. But that's not being inside another's next thing. What about the aducanumab trials? No. What about the value-based contracts? Those are with payers, but that's not a future product. What about the mention of "we are collaborating with Siemens to develop new MRI tools" - that's a collaboration, but not a secured position. What about the mention of "we are working with physicians" etc. The question specifically asks: "does management describe that the company has ALREADY BEEN CHOSEN, SPECIFIED, QUALIFIED, DESIGNED IN, OR OTHERWISE LOCKED INTO POSITION INSIDE ANOTHER ORGANIZATION'S FUTURE PRODUCT, PROGRAM, PLATFORM, BUILD-OUT, OR STANDARD OPERATING PLAN" - such that when that outside party's own next wave of activity arrives, this company's volume arrives with it automatically. Look for any such description. For example, Biogen's SPINRAZA is a product, but that's Biogen's own. Not. What about the collaboration with Penn for gene therapy? That's early stage. What about the mention of "we are working with physicians to understand best practices" - no. What about the mention of "SMA was accepted into the review process for the Recommended Uniform Screening Panel" - that's about newborn screening guidelines. That could be a case where Biogen's therapy is designed into a future standard of care? But that's not a specific organization's product. It's a guideline.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NC | NACCO Industries, Inc. | Q1 2024 | 2024-05-05 | C+ |
| CLGN | CollPlant Biotechnologies Ltd. | Q4 2023 | 2024-04-04 | F |
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| AIRG | Airgain, Inc. | Q3 2023 | 2023-11-09 | F |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
| THRM | Gentherm Incorporated | Q2 2016 | 2016-07-28 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| SPR | Spirit AeroSystems Holdings, Inc. | Q1 2016 | 2016-04-29 | D |
CUBI · Q3 2018 → YESThe question is about whether management describes that the company has already been chosen or locked into another organization's future product/program, such that volume will come automatically when ...NO The transcript describes a white-label partnership with T-Mobile where BankMobile provides services under T-Mobile's brand, with deposits expected to start in the next year after the launch. However, this does not meet the criteria for a secured position inside T-Mobile's next product or program. The language focuses on a partnership relationship that is still being launched, rather than a design win or qualification already embedded in T-Mobile's future offering. Management refers to it as an "expected white label partnership" and "working on" the launch, indicating it is not yet locked in as part of T-Mobile's committed plan.
EMKR · Q4 2023 → YESThe question is about whether management describes that the company has already been chosen or locked into another organization's future product/program, such that volume will come automatically when ...NO The transcript describes an agreement with Kratos for Inertial Navigation Systems to be included in the XQ58 Valkyrie drone, with the Air Force planning to acquire at least 1,000 units. However, this is framed as an announcement of a new agreement rather than a secured, locked-in position already designed 100% into the platform with volume guaranteed.
NC · Q1 2024 → YESThe question is about whether management describes that the company has already been chosen or locked into another organization's future product/program, such that volume will arrive automatically whe...